 |
90 Diseases |  |
4 Trials |
|
4 Trials |  |
194 News |  |
| «1234» |
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment open: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Dec 29, 2016
P3, N=330, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Dec 19, 2016
P3, N=330, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Phase classification: P2 --> P3 | N=140 --> 330
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Phase classification: P2 --> P3 | N=140 --> 330 Trial primary completion date: May 2018 --> Dec 2018
- ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification, Combination therapy, Metastases: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (clinicaltrials.gov) - Nov 3, 2016
P1b/2, N=89, Terminated, Sponsor: NantCell, Inc.
Trial primary completion date: May 2018 --> Dec 2018 Phase classification: P1/2 --> P1b/2
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Nov 1, 2016
P2, N=140, Suspended, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P1b/2 Recruiting --> Suspended
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification, Combination therapy: QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Oct 27, 2016
P1b/2, N=204, Completed, Sponsor: NantCell, Inc.
Recruiting --> Suspended Phase classification: P1/2 --> P1b/2
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification, Combination therapy, Metastases: QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 27, 2016
P1b/2, N=138, Completed, Sponsor: NantCell, Inc.
Phase classification: P1/2 --> P1b/2 Phase classification: P1/2 --> P1b/2
- ganitumab (AMG 479) / Takeda, ImmunityBio
Phase classification: QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 27, 2016
P1b, N=46, Completed, Sponsor: NantCell, Inc.
Phase classification: P1/2 --> P1b/2 Phase classification: P1 --> P1b
- || ganitumab (AMG 479) / Takeda, ImmunityBio, Vectibix (panitumumab) / Amgen
Trial primary completion date: A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 (clinicaltrials.gov) - Jul 19, 2016
P1, N=100, Recruiting, Sponsor: Herbert Hurwitz, MD
Phase classification: P1 --> P1b Trial primary completion date: Apr 2016 --> Jun 2017
- || ganitumab (AMG 479) / Takeda, ImmunityBio
Trial primary completion date, Metastases: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 19, 2016
P2, N=60, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Apr 2016 --> Jun 2017 Trial primary completion date: Nov 2014 --> Aug 2016
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Nov 2014 --> Aug 2016 N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018
- Piqray (alpelisib) / Novartis
Trial primary completion date: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - Jun 28, 2016
P1/2, N=47, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018 Trial primary completion date: Jun 2016 --> Jun 2017
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - May 9, 2016
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Jul 2016 --> Jan 2017
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial primary completion date, Combination therapy, Metastases: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 19, 2016
P1, N=30, Active, not recruiting, Sponsor: Shadia Jalal
Trial primary completion date: Jul 2016 --> Jan 2017 Trial primary completion date: Jun 2015 --> Feb 2014
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Nov 27, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Jun 2015 --> Feb 2014 Trial primary completion date: Dec 2015 --> Jul 2016
- Piqray (alpelisib) / Novartis
Trial primary completion date: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - Nov 10, 2015
P1/2, N=47, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Sep 2016 --> Jun 2016
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial primary completion date, Combination therapy, Metastases: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 31, 2015
P1, N=30, Active, not recruiting, Sponsor: Indiana University
Trial primary completion date: Sep 2016 --> Jun 2016 Trial primary completion date: Jan 2015 --> Jun 2015
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=1200, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Jan 2015 --> Jun 2015 N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017
- |||| Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion, Trial primary completion date, Metastases: A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors (clinicaltrials.gov) - May 19, 2015
P2, N=77, Completed, Sponsor: Novartis Pharmaceuticals
N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Apr 2015
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Apr 20, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Apr 2015 Trial primary completion date: Apr 2015 --> Dec 2015
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial termination, Trial primary completion date: Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer (clinicaltrials.gov) - Mar 7, 2015
P2, N=170, Terminated, Sponsor: Cancer International Research Group
Trial primary completion date: Apr 2015 --> Dec 2015 Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Sep 2013; The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial.
- | conatumumab (AMG 655) / Amgen
Enrollment closed, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 20, 2015
P2, N=12, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Sep 2013; The steering committee of the TRIO014 study has taken the decision to stop the TRIO014 trial. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015 Trial primary completion date: Dec 2015 --> Dec 2018
- ganitumab (AMG 479) / Takeda, ImmunityBio
Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Jan 2, 2015
P2, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2018 Not yet recruiting --> Recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 9, 2014
P1, N=30, Active, not recruiting, Sponsor: Indiana University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jan 2015
- | ganitumab (AMG 479) / Takeda, ImmunityBio
New P3 trial: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Dec 6, 2014
P2, N=140, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Piqray (alpelisib) / Novartis
Enrollment closed, Enrollment change: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=47, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2014 --> Jan 2015 Recruiting --> Active, not recruiting | N=70 --> 47
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Sep 22, 2014
P2, N=800, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Recruiting --> Active, not recruiting | N=70 --> 47 Trial primary completion date: Feb 2014 --> Sep 2015
- || Piqray (alpelisib) / Novartis
Trial primary completion date: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - May 18, 2014
P1/2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2014 --> Sep 2015 Trial primary completion date: May 2015 --> Sep 2016
- || Piqray (alpelisib) / Novartis
Trial completion date: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - May 18, 2014
P1/2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2015 --> Sep 2016 Trial completion date: Nov 2015 --> Sep 2016
- || ganitumab (AMG 479) / Takeda, ImmunityBio
Trial primary completion date, Metastases: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - May 1, 2014
P2, N=60, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Nov 2015 --> Sep 2016 Trial primary completion date: Nov 2013 --> Nov 2014
- ||| Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Metastases: A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors (clinicaltrials.gov) - Mar 30, 2014
P2, N=77, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2013 --> Nov 2014 Recruiting --> Active, not recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Metastases: Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas (clinicaltrials.gov) - Jan 22, 2014
P1, N=8, Completed, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jan 21, 2014
P1/2, N=142, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab (clinicaltrials.gov) - Jan 12, 2014
P2, N=76, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Oct 29, 2013
P2, N=61, Completed, Sponsor: Cancer International Research Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment change, Metastases: Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas (clinicaltrials.gov) - Oct 28, 2013
P1, N=8, Completed, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed N=42 --> 8
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Jun 12, 2013
P2, N=38, Completed, Sponsor: Amgen
N=42 --> 8 Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Combination therapy, Metastases: QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma (clinicaltrials.gov) - Apr 11, 2013
P2, N=155, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Combination therapy: QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Apr 11, 2013
P1/2, N=204, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ganitumab (AMG 479) / Takeda, ImmunityBio
Trial withdrawal, Metastases: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Completed --> Withdrawn
- ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment change, Metastases: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: Cancer and Leukemia Group B
Completed --> Withdrawn N=200 --> 0
- | conatumumab (AMG 655) / Amgen
Enrollment change: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
N=200 --> 0 N=30 --> 12
- | conatumumab (AMG 655) / Amgen
Enrollment open: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 13, 2013
P2, N=12, Recruiting, Sponsor: Amgen
N=30 --> 12 Active, not recruiting --> Recruiting
- |||| Piqray (alpelisib) / Novartis
Enrollment open: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - Jan 27, 2013
P1/2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio
Enrollment closed: Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer (clinicaltrials.gov) - Jan 27, 2013
P2, N=160, Active, not recruiting, Sponsor: Cancer International Research Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion, Combination therapy, Metastases: QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 28, 2012
P1/2, N=138, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Piqray (alpelisib) / Novartis
New P1/2 trial: A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors (clinicaltrials.gov) - Oct 14, 2012
P1/2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
- ganitumab (AMG 479) / Takeda, ImmunityBio, Herceptin (trastuzumab) / Roche
Trial withdrawal: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- ganitumab (AMG 479) / Takeda, ImmunityBio, Herceptin (trastuzumab) / Roche
Enrollment change: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab (clinicaltrials.gov) - Oct 1, 2012
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=35 --> 0